Golimumab is usually a human monoclonal antibody administered once a month by subcutaneous injection. Although it's the same security and efficacy profile to other TNFi, golimumab is much less effective than other TNFi in individuals who have failed numerous biological therapies. The latest therapeutic approach to RA accepted through the https://www.directivepublications.org/journal-of-arthritis-and-rheumatology/